Vericel Corporation
Rank #129Op. LeverageVCEL · Nasdaq · Healthcare
Vericel Corporation (VCEL) — Rank #129 by gross profitability (GP/assets 0.41) · ROE 4.5% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0000887359 · all metrics point-in-time as of the filing date.
About
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Show moreShow less
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.
The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- MI
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- vcel.com
Segments
A revenue-by-segment breakdown is not available for VCEL. This is expected for a single-reportable-segment filer with no product/service revenue disaggregation, or for a company whose filings predate SEC’s XBRL viewer.